Monte Rosa Therapeutics, Inc. (GLUE)
- Sector
- Biotechnology
- Last price
- $9.07
- As of
Kresmion compiles this page from GLUE's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Monte Rosa Therapeutics, Inc. (GLUE): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-05.
See the full GLUE dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for GLUE on one page. Preview it with sample data, then open it live with a free account.
Preview the GLUE dossierActive events for GLUE
- mediumEarnings above estimates
Q3-2026: Beat consensus by 110.1%, EPS $0.03 vs $-0.2973 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 55% of GLUE (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +739% to GLUE (2026Q2)
- high13F: large reduction
RENAISSANCE TECHNOLOGIES LLC cut 73% of GLUE (2026Q2)
- high13F: large increase
D. E. Shaw & Co., Inc. added +159% to GLUE (2026Q2)
FREE, NO ACCOUNT
Every event on GLUE, as it fires
You are seeing 5 of 11 events recorded on GLUE since 2026-05-29.
The five above landed across 2 days. The other 6 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, GLUE
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on GLUE
GLUE against its peers
GLUE's operating margin of -43.8% ranks in the 46th percentile of 11 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | GLUE | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 124M USD | 107M USD | 54 | 11 |
| Operating margin | -43.8% | -10.1% | 46 | 11 |
| Net margin | -31.2% | -15.1% | 46 | 11 |
| Return on equity | -16.6% | -41.4% | 68 | 16 |
| 1 year | -35.2% | 17.2% | 21 | 16 |
Peers (18): IRWD, ARDX, ORIC, LXRX, PRME, SNDX, SLDB, AURA, RIGL, JANX, MGTX, SGMT, CRVS, TBPH, XOMA.D, PHAR, NVCT, ACHV. Left out: OBX (no annual filing), LTGO (no annual filing), BBTX (no annual filing), IVA (period gap), AKTS (no annual filing), ATTO (no annual filing), CTY (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (GLUE: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in GLUE on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on GLUE in the last 180 days.
Upstream: SEC EDGAR filings for GLUE
Kresmion, "Monte Rosa Therapeutics, Inc. (GLUE) institutional holdings and SEC filings", data as of 2026-11-11, https://kresmion.com/research/GLUE. Upstream data: SEC EDGAR filings for GLUE.
Link to this data (HTML):
<a href="https://kresmion.com/research/GLUE">Monte Rosa Therapeutics, Inc. (GLUE) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow GLUE on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to GLUE for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.